SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation

Katherine R. Tuttle, Frank C. Brosius, Matthew A. Cavender, Paola Fioretto, Kevin J. Fowler, Hiddo J.L. Heerspink, Tom Manley, Darren K. McGuire, Mark E. Molitch, Amy K. Mottl, Leigh Perreault, Sylvia E. Rosas, Peter Rossing, Laura Sola, Volker Vallon, Christoph Wanner, Vlado Perkovic

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Diabetes is the most frequent cause of chronic kidney disease (CKD), leading to nearly half of all cases of kidney failure requiring replacement therapy. The principal cause of death among patients with diabetes and CKD is cardiovascular disease (CVD). Sodium/glucose cotransporter 2 (SGLT2) inhibitors were developed to lower blood glucose levels by inhibiting glucose reabsorption in the proximal tubule. In clinical trials designed to demonstrate the CVD safety of SGLT2 inhibitors in type 2 diabetes mellitus (T2DM), consistent reductions in risks for secondary kidney disease end points (albuminuria and a composite of serum creatinine doubling or 40% estimated glomerular filtration rate decline, kidney failure, or death), along with reductions in CVD events, were observed. In patients with CKD, the kidney and CVD benefits of canagliflozin were established by the CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) trial in patients with T2DM, urinary albumin-creatinine ratio > 300 mg/g, and estimated glomerular filtration rate of 30 to <90 mL/min/1.73 m2. To clarify and support the role of SGLT2 inhibitors for treatment of T2DM and CKD, the National Kidney Foundation convened a scientific workshop with an international panel of more than 80 experts. They discussed the current state of knowledge and unanswered questions to propose therapeutic approaches and delineate future research. SGLT2 inhibitors improve glomerular hemodynamic function and are thought to ameliorate other local and systemic mechanisms involved in the pathogenesis of CKD and CVD. SGLT2 inhibitors should be used when possible by people with T2DM to reduce risks for CKD and CVD in alignment with the clinical trial entry criteria. Important risks of SGLT2 inhibitors include euglycemic ketoacidosis, genital mycotic infections, and volume depletion. Careful consideration should be given to the balance of benefits and harms of SGLT2 inhibitors and risk mitigation strategies. Effective implementation strategies are needed to achieve widespread use of these life-saving medications.

Original languageEnglish (US)
Pages (from-to)94-109
Number of pages16
JournalAmerican Journal of Kidney Diseases
Volume77
Issue number1
DOIs
StatePublished - Jan 2021

Keywords

  • Hyperglycemia
  • SGLT2 inhibitor
  • atherosclerotic cardiovascular disease (ASCVD)
  • diabetic kidney disease (DKD)
  • heart failure (HF)
  • kidney protection
  • major adverse cardiovascular events (MACE)
  • renal function preservation
  • research priorities
  • review
  • sodium/glucose cotransporter 2 (SGLT2)

ASJC Scopus subject areas

  • Nephrology

Fingerprint

Dive into the research topics of 'SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation'. Together they form a unique fingerprint.

Cite this